Genmab — Maj 2023
-
Torsdagens markante kursfremgang i Genmab skyldes næppe kvartalsregnskabet onsdag efter børslukketid, men snarere spekulationer om en mulig opjustering af Genmabs vægt i KAX Cap-indekset.
Det vurderer Genmab-analytiker i Jyske Bank Henrik Hallengreen Laustsen over for MarketWire. -
Manden må have spist søm. En opvægtning i et indeks giver ikke en stigning på 6,6%…
-
Analytiker om stort kurshop i Genmab: Kan have rod i håb om øget indeksvægt https://www.proinvestor.com/investornyt/983616/analytiker-om-stort-kurshop-i-genmab-kan-have-rod-i-hab-om-oget-indeksvaegt
-
GEN3014 (HexaBody
-CD38) updated https://clinicaltrials.gov/ct2/history/NCT04824794?A=3&B=4&C=Side-by-Side#StudyPageTop not sure why Participants in the US will not participate in the Dara SC comparison -
Kort video: ALK-Abelló ' Bavarian Nordic ' Genmab ' Lundbeck ' Zealand Pharma ' Hansa Biopharma
Der er fest på ProInvestor.com - for næsten alle de mest populære pharma- og biotekselskaber på sitet er steget i kurs. https://www.proinvestor.com/boards/112581
-
Er short i usa på ADR regnet med i Finanstilsynets opgørelse. Lige nu, svarer antal shortede i USA ret nøjagtigt til opgørelsen fra Finanstilsynet?
-
ja
-
Takker, @LLi
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind